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ABSTRACT Lipid II is an essential precursor for bacterial cell wall biosynthesis and
thereby an important target for various antibiotics. Several lanthionine-con-
taining peptide antibiotics target lipid II with lanthionine-stabilized lipid II binding
motifs. Here, we used the biosynthesis system of the lantibiotic nisin to synthesize a
two-lipid II binding motifs-containing lantibiotic, termed TL19, which contains the
N-terminal lipid II binding motif of nisin and the distinct C-terminal lipid II binding
motif of one peptide of the two-component haloduracin (i.e., HalA1). Further charac-
terization demonstrated that (i) TL19 exerts 64-fold stronger antimicrobial activity
against Enterococcus faecium than nisin(1-22), which has only one lipid II binding
site, and (ii) both the N- and C-terminal domains are essential for the potent antimi-
crobial activity of TL19, as evidenced by mutagenesis of each single and the double
domains. These results show the feasibility of a new approach to synthesize potent
lantibiotics with two different lipid II binding motifs to treat specific antibiotic-
resistant pathogens.
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Lantibiotics are potent lanthionine-containing antimicrobial peptides that are ribo-somally synthesized and posttranslationally modified (RiPPs) (1). The ribosomal
synthesis and enzymatic modifications installed by lantibiotic enzymes provide a
powerful discovery platform to develop novel antimicrobial peptides with high thera-
peutic potential (2). One of the best-studied lantibiotics is nisin. Its synthesis is con-
trolled by the NisRK two-component regulatory system (3). In this system, nisin induces
the nisin operon at the nisin A promoter via the NisRK signal-transduction system, thus
controlling the expression of the genes coding for prenisin, the dehydratase NisB, the
cyclase NisC, and the transporter NisT or any cloned gene of interest (4). The nisin
biosynthetic system has a wide substrate tolerance; a variety of precursor peptides can
be modified by this biosynthetic machinery when fused to the leader peptide of nisin
(5–9). Therefore, this system is very well suited and convenient for engineering lantibi-
otics.
To engineer a lantibiotic containing two lipid II binding sites, we made use of the
lantibiotics nisin, haloduracin, and lacticin A as the templates. Nisin is a 34-residue RiPP
produced by various Lactococcus lactis strains (Fig. 1a). The two N-terminal rings of nisin
physically interact with lipid II, resulting in formation of nisin-lipid II hybrid pores in the
target membrane and inhibition of cell wall synthesis via lipid II abduction (10, 11).
Haloduracin and lacticin 3147 are both two-peptide lantibiotics composed of HalA1 and
HalA2 and LtnA1 and LtnA2, respectively. Both two-peptide lantibiotics have high
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antimicrobial potency against a range of Gram-positive bacteria (8, 12–14). Notably, the
single peptides of the pair are devoid of antimicrobial activity. HalA1 and LtnA1 both
contain a CTLTXEC lipid II binding motif (Fig. 1b and d). Variants with mutations in
this area have reduced or even abolished antimicrobial activity (12, 13, 15, 16). The
N-terminal lipid II binding site of nisin (Fig. 1a, green part) and the C-terminal lipid II
binding site of HalA1 and LtnA1 (Fig. 1b and d, green parts) provide an opportunity to
engineer lantibiotics with two lipid II binding motifs.
Lipid II (GlcNAc-MurNAc-pentapeptide-pyrophosphoryl-undecaprenol) (Fig. 1e)
plays an essential role in the synthesis of the bacterial cell wall (11, 17). The crucial role
of lipid II in cell wall synthesis makes it an excellent target for many antibiotics,
including vancomycin, ramoplanin, mannopeptimycins, and teixobactin, and a number
of lantibiotics, including: nisin, NAI-107, gallidermin, nukacin ISK-1, mersacidin, halodu-
racin, and lacticin A (11–20). A large number of potent antibiotics have the lipid II
binding motif and bind lipid II in a 2:1 stoichiometry (14, 17, 19, 21–26). Only NAI-107,
a very effective lantibiotic that will soon be tested in clinical trials, appears to bind
in a 1:1 stoichiometry. Notably, while the short nisin(1-12) fragment is inactive, a
vancomycin-nisin(1-12) hybrid is active against vancomycin-resistant enterococci (27).
As lipid II is an important target, it is of interest to study whether molecules with two
different lipid II binding motifs display enhanced antimicrobial activity and/or exert
altered specificity for difficult-to-treat target organisms. In this study, the nisin biosyn-
thetic system was used to produce, modify, and secrete designed lantibiotics with two
lipid II binding motifs. The following aspects of these lantibiotics were investigated:
lipid II binding, bacterial killing, ability to form pores, and structure-dependent antimi-
crobial activity against pathogenic microorganisms. Taken together, the study demon-
strates that the combination of two different lipid II binding motifs in engineered
FIG 1 Structures of some lipid II binding lantibiotics and lipid II. Residues known to be involved in lipid II binding are colored green. (a)
Nisin is a natural lantibiotic produced by various Lactococcus lactis strains. (b) HalA1 is one of the peptides of the natural two-component
lantibiotic haloduracin, which is produced by Bacillus halodurans C-125. (c) Nisin(1-22) is a truncated synthetic lantibiotic derived from
nisin. (d) LtnA1 is one of the peptides of the natural two-component lantibiotic lacticin 3147, which is produced by Lactococcus lactis
subsp. lactis DPC3147. (e) Structure of Gram-positive and Gram-negative lipid II.
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lantibiotics provides a novel and viable approach in the discovery of effective lantibi-
otics.
RESULTS
Expression of lanthipeptides with two lipid II binding motifs. The designed
peptides are composed of the N-terminal lipid II binding site of nisin (Fig. 1a, green
part), the C-terminal lipid II binding site of either haloduracin (HalA1) or lacticin 3147
(LtnA1) (Fig. 1b and d, green parts), and appropriate linkage between these domains
(Table 1). DNA sequencing confirmed the correct sequence of all 20 double lipid II
binding motifs-containing peptides. All 20 designed peptides (Table 1) were produced
and efficiently modified by the dehydratase NisB; more than 75% of Thr and Ser
residues were dehydrated (Table 1). Two of the modified candidates (TL17 and TL19)
showed potent antimicrobial activity against Micrococcus flavus (see Fig. S1 in the
supplemental material), and both of these peptides were correctly dehydrated as
predicted (Table 1). NisC-mediated cyclization was investigated using free cysteine-
modifying 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) under reduc-
ing conditions followed by mass spectrometry (MS) analysis. No adducts were observed
for the TL19 main product, indicating that all cysteines had reacted with dehydroamino
acids to form (methyl)lanthionines (Fig. 2b). However, CDAP adducts were observed in
TL17 (Fig. 2a), indicating that not all rings had been formed. These results suggest a
likely TL19 structure (Fig. 2c), a lantibiotic with seven thioether rings and two potential
lipid II binding motifs. Mass spectrometry demonstrated TL17 and TL19 were correctly
collected by high-performance liquid chromatography (HPLC) purification (see Fig. S2).
TL19 exerts high activity against antibiotic-resistant Enterococcus faecium. The
antibacterial activities of TL17 and TL19 were measured by a MIC assay. Due to its ability
to form pores in the target cell membrane and to inhibit cell wall synthesis, nisin (Fig.
1a) is a very potent lantibiotic (10). Nisin(1-22) (Fig. 1c) is unable to form pores, only
binds to lipid II, and thereby halts cell growth without killing the cells (28). Therefore,
in the MIC assays, nisin was used as a well-known antibiotic control, and nisin(1-22) was
used as a one-lipid II binding motif-containing lantibiotic control with relatively low
TABLE 1 Amino acid sequence and dehydrations of designed peptides




TL1 ITSISLCTPGCTLTVECMPSCN 5,453.16 5,452.5 6/6
TL2 ITSISLCTPGCTLTHECMAWCK 5,578.33 5,596.12 5/6
TL3 ITSISLCTPGCKTGALMYCTLTVECMPSCN 6,303.22 6,302.93 7/7
TL4 ITSISLCTPGCKTGALMWCTLTHECMAWCK 6,451.53 6,469.35 6/7
TL5 ITSISLCTPGCKTGALMGCTLTVECMPSCN 6,197.10 6,196.88 7/7
TL6 ITSISLCTPGCKTGALMGCTLTHECMAWCK 6,322.27 6,340.12 6/7
TL7 ITSISLCTPGCKTGALMGYCTLTVECMPSCN 6,360.27 6,360.54 7/7
TL8 ITSISLCTPGCKTGALMGWCTLTHECMAWCK 6,508.48 6,526.11 6/7
TL9 ITSISLCTPGCKTCRLGNKGAYCTLTVECMPSCN 6,730.67 6,729.89 7/7
TL10 ITSISLCTPGCKSCRLGNKGAYCTLTVECMPSCN 6,716.65 6,716.24 7/7
TL11 ITSISLCTPGCKTDYWGNNGAWCTLTHECMAWCK 6,956.80 6,957.34 7/7
TL12 ITSISLCTPGCKSDYWGNNGAWCTLTHECMAWCK 6,942.77 6,969.10 6/7
TL13 ITSISLCTPGCKTGALMGCNMKTAGCTLTVECMPSCN 6,884.92 6,884.21 8/8
TL14 ITSISLCTPGCKTGALMGCNMKTAGCTLTHECMAWCK 7,010.09 7,027.98 7/8
TL15 ITSISLCTPGCKTGALMGCNMKTAGYCTLTVECMPSCN 7,048.09 7,065.84 7/8
TL16 ITSISLCTPGCKTGALMGCNMKTAGWCTLTHECMAWCK 7,196.30 7,214.05 7/8
TL17 ITSISLCTPGCKTGALMGCNMKTATCHCTLTVECMPSCN 7,151.24 7,150.87 9/9
TL18 ITSISLCTPGCKTGALMGCNMKTATCHCTLTHECMAWCK 7,276.42 7,311.80 7/9
TL19 ITSISLCTPGCKTGALMGCNMKTATCHYCTLTVECMPSCN 7,314.41 7,315.06 9/9
TL20 ITSISLCTPGCKTGALMGCNMKTATCHWCTLTHECMAWCK 7,462.63 7,480.25 8/9
TL19 (2Asp) IDSISLCTPGCKTGALMGCNMKTATCHYCTLTVECMPSCN 7,346.67 7,364.27 7/8
TL19 (34Ala) ITSISLCTPGCKTGALMGCNMKTATCHYCTLTVACMPSCN 7,256.65 7,257.13 9/9
TL19 (2Asp, 34Ala) IDSISLCTPGCKTGALMGCNMKTATCHYCTLTVACMPSCN 6,334.59 6,351.82 7/8
aFor peptides TL1 to TL20, the amino acids from the N terminus of nisin are underlined; the amino acids from the C terminus of haloduracin A1 are italicized; and the
amino acids from the C terminus of lacticin A1 are without any special format. The mutated amino acids of TL19 mutations are underlined and italicized.
bThe major assay products with predicted dehydration are in boldface font. Dehydration of Ser/Thr is the first step in the lanthionine ring formation.
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activity. Both TL17 and TL19 displayed potent activity against Gram-positive pathogens,
including difficult-to-treat enterococci (Table 2). TL17 and TL19 were much more active
against most target bacteria than nisin(1-22) (Table 2), which has only one lipid II
binding motif and which is devoid of pore-forming capacity (28). In particular, TL17 and
TL19 displayed higher antimicrobial activity against E. faecium, Enterococcus faecalis,
and Bacillus cereus. TL17 and TL19 had potent antibacterial activity against antibiotic-
resistant E. faecium and had 16-fold and 64-fold higher antibacterial activity, respec-
tively, than nisin(1-22). Moreover, TL19 had a 2- to 4-fold lower MIC value against most
of the E. faecium strains tested than native nisin, which not only binds lipid II but also
forms pores (11, 17). TL17 and TL19 were ineffective against most Gram-negative
bacteria. However, TL19 showed antimicrobial activity against a strain of Acinetobacter
baumannii. In contrast to TL19, TL17 was incompletely modified and exerted lower
antimicrobial activity against the tested pathogens (Table 2 and Fig. 2a; see also Fig. S3).
Therefore, TL19 was selected for further studies, in particular, on its mode of action.
Time-dependent killing of E. faecium by TL19. Measuring the time dependence
of antibiotic action is widely used to establish whether a compound is bacteriostatic or
bactericidal (22, 29). In this study, we monitored the killing kinetics of the engineered
peptide TL19 and a number of other lantibiotics against vancomycin-resistant E.
faecium cells. Due to its ability to form pores in the target cell membrane, together with
cell wall biosynthesis inhibition, nisin is well known as a bactericidal lantibiotic (10).
However, nisin(1-22) is unable to form pores and only halts cell growth without killing
FIG 2 MALDI-TOF MS data of TL17 and TL19 before (blue) and after (red) treatment with CDAP. (a) TL17; (b) TL19; (c) hypothetical structure of
TL19.
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the cells (28). The time-dependent killing assay showed that TL19 had caused complete
killing at 24 h postexposition (Fig. 3). Nisin(1-22) did not reduce the population of viable
cells within 11 h postexposition, and only slight killing was observed in 48 h (Fig. 3).
Nisin acted faster than TL19 and much faster than nisin(1-22), significantly reducing the
population of viable cells until completely killing all cells within 11 h. The results
demonstrated that TL19 not only halts cell division, like nisin(1-22), but also reduces the
population of viable bacterial cells.
TL19 does not form pores. To assess pore-forming capacity of TL19 on whole-cell
membranes, a pore formation assay was performed using the dye propidium iodide
(Fig. 4a). Propidium iodide is a cell membrane-impermeable nucleic acid-intercalating
dye. Upon pore formation in the cell membrane, this dye enters the cell and binds to
nucleic acids in the cytoplasm, causing an increase in fluorescence. Immediate pore
formation was observed when E. faecium 16003 cells pretreated with propidium iodide
were exposed to nisin, which not only binds lipid II but also forms pores (11, 17),
whereas addition of neither TL19 nor nisin(1-22) caused any fluorescence increase, even
after a relatively long period of 3 h (30). These results indicate that TL19, under the
experimental conditions applied, does not form pores in the cellular membrane.
TABLE 2 Antimicrobial activity of TL17 and TL19 against pathogenic microorganisms
Organism and typea
MIC (M [g/ml])b
Nisin Nisin(1-22) TL17 TL19
E. faecium LMG16003 (VRE) 1.9 (6.4) 60 (128) 3.8 (14.7) 0.9 (3.6)
E. faecium LMG11423 1.9 (6.4) 60 (128) 3.8 (14.7) 0.9 (3.6)
E. faecium ATCC E1321 (AGRE) 1.9 (6.4) 60 (128) 3.8 (14.7) 0.9 (3.6)
E. faecium ATCC TX0133a04 1.9 (6.4) 60 (128) 3.8 (14.7) 0.9 (3.6)
E. faecium ATCC TX0082 (AEKVRE) 1.9 (6.4) 60 (128) 3.8 (14.7) 0.9 (3.6)
E. faecium 4Tom19 1.9 (6.4) 60 (128) 3.8 (14.7) 0.9 (3.6)
E. faecium 6Tom18 1.9 (6.4) 30 (64) 1.9 (7.3) 0.5 (2)
E. faecium ATCC HF50105 (ETVRE) 1.9 (6.4) 30 (64) 1.9 (7.3) 0.5 (2)
E. faecium ATCC U0317 (ACRE) 3.8 (12.7) 60 (128) 7.5 (29) 1.9 (7.6)
E. faecium ATCC E1162 (ARE) 3.8 (12.7) 60 (128) 7.5 (29) 1.9 (7.6)
E. faecalis LMG8222 1.9 (6.4) 60 (128) 15 (58) 7.5 (30)
E. faecalis LMG16216 (VRE) 1.9 (6.4) 60 (128) 15 (58) 15 (60)
E. faecalis LMGV583 1.9 (6.4) 60 (128) 15 (58) 7.5 (30)
S. aureus LMG10147 3.8 (12.7) 15 (32) 15 (58) 7.5 (30)
B. cereus ATCC 10987 1.9 (6.4) 60 (128) 15 (58) 15 (60)
B. cereus ATCC 14579 1.9 (6.4) 30 (64) 15 (58) 15 (60)
A. baumannii LMG01041 3.8 (12.7) 60 (128) 15 (58) 7.5 (30)
Escherichia coli GSK 12 15 (50) 60 (128) 15 (58) 15 (60)
aVRE, vancomycin-resistant enterococci; AGRE, ampicillin-gentamicin-resistant enterococci; AEKVRE, ampicillin-
erythromycin-kanamycin-vancomycin-resistant enterococci; ETVRE, erythromycin-tetracycline-vancomycin-
resistant enterococci; ACRE, ampicillin-ciprofloxacin-resistant enterococci; ARE, ampicillin-resistant
enterococci.
bThe MIC was determined by broth microdilution. Nisin was used as a well-known antibiotic control, and
nisin(1-22) was used as a one-lipid II binding motif lantibiotic control.
FIG 3 Time-dependent killing of pathogens by TL19, nisin, and nisin(1-22). E. faecium (LMG16003;
vancomycin-resistant strain) was challenged with lantibiotics (10 MIC). Data are representative of 3
independent experiments  the standard deviation (SD).
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TL19 has two functional lipid II binding domains. The direct interaction of TL19
with Gram-positive lipid II (lipid II-lys) or Gram-negative lipid II (lipid II-dap) was
investigated. Purified lipid II-lys or lipid II-dap was incubated with TL19 in various molar
ratios ranging from 0.3 to 2 (TL19/lipid II). Subsequent thin-layer chromatography was
used to analyze the migration behavior (Fig. 4b1 and b2). Free lipid II migrated to a
defined position (Fig. 4b1 and b2, first lane). However, in complex with TL19, lipid II
remained at the origin line as a clear spot (Fig. 4b1 and b2, 2nd to 4th lanes). Already
at a low ratio (0.3:1) of TL19 to lipid II, lipid II migration was significantly inhibited. At
a 1:1 ratio of lipid II and TL19, both lipid II-lys and lipid II-dap were fully trapped in a
stable complex that prevented migration of lipid II from the origin line. Interestingly,
the stoichiometry of both nisin and two-component haloduracin to lipid II reported in
earlier studies is 2:1 (11, 16). Further studies were performed by a spot-on-lawn assay
(Fig. 4c and d). Addition of either lipid II-lys or lipid II-dap at a 1:1 (nisin/lipid II) ratio
abolished the antibacterial activity of nisin against E. faecium LMG16003. In sharp
contrast to nisin, TL19 still showed potent antibacterial activity against E. faecium
LMG16003 upon addition of either lipid II-lys or lipid II-dap at a 1:1 (TL19/lipid II) ratio.
The antibacterial activity of TL19 against indicator strains was only abolished by further
addition of lipid II resulting in a 1:2 ratio (TL19/lipid II). These results indicated that TL19
has two active lipid II binding domains.
FIG 4 (a) E. faecium LMG16003 cells pretreated with propidium iodide were exposed to antimicrobial peptides (3 M), and
the extent of membrane leakage was visualized as an increase in fluorescence. (b) TL19 binds to cell wall precursors.
Complex formation of TL19 with purified cell wall precursors at the origin are at the bottom. Binding of TL19 is indicated
by a reduction of the amount of free lipid II intermediates (visible at the top on the thin-layer chromatogram). The figure
is representative of two independent experiments. (c and d) Spot-on-lawn assays with E. faecium LMG16003 cells. Lipid II
reduces TL19 or nisin activity by a lantibiotic/lipid II ratio-dependent reduction/disappearance of the zone of inhibition.
Neither lipid II-lys nor lipid II-dap disrupted the diffusion of a non-lipid II binding peptide antibiotic, bogorol k, in the agar.
Lipid II alone did not show activity.
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Both lipid II binding domains of TL19 contribute to antibacterial activity. A
highly conserved glutamate in HalA1 (Glu22) is essential for binding to its target lipid
II (12, 15, 16). Mutating the glutamate residue in the CTLTXEC motif to alanine or
glutamine completely abolished antibacterial activity (15). Recently, we found that
exchange of the Thr2 residue in nisin’s lipid II binding motif with aspartic acid or
glutamic acid decreased or completely abolished nisin’s antibacterial activity (see Fig.
S4). Therefore, either Glu34 in TL19 was mutated to Ala, Thr2 in TL19 was mutated to
Asp, or both mutations were installed together in the same TL19 variant. Exchange of
the threonine residue in TL19 (Thr2) with aspartic acid caused a loss of one dehydration
in the peptide; mutation of the glutamate residue in TL19 (Glu34) to Ala did not affect
the extent of dehydration (Table 1). NisC-catalyzed cyclization of the mutated peptides
was investigated using CDAP treatment under reducing conditions followed by MS
analysis. No adducts were observed for the TL19 main product; however, CDAP adducts
were observed in all the mutated peptides (Fig. 2 and 5). Bioactivity analysis after
removal of the leader peptide with the NisP leader peptidase demonstrated a strong
decrease in antibacterial activity for both single-amino-acid mutant peptides and a
complete abolishment of activity for the double amino acid mutant under the condi-
tions used (Fig. 5d). Moreover, combination of the two single-mutant species in one
assay did not show any synergistic antimicrobial activity. These data prove that both
lipid II binding domains are important for antibacterial activity, by binding to lipid II.
DISCUSSION
Lipid II binding lantibiotics show potent antibacterial activity by binding to lipid II
and subsequently inhibiting cell wall synthesis and pore formation in the cell mem-
brane (11, 12, 14, 20, 31). The lipid II binding motif of this class of antibiotics is essential
for their potent antimicrobial activity (see Fig. S4 in the supplemental material) (13, 15).
Here, we show how a lantibiotic with two different lipid II binding motifs was engi-
neered, which showed 64-fold stronger antimicrobial activity against difficult-to-treat
enterococci than the activity of a one lipid II binding motif-containing lantibiotic,
nisin(1-22) (Table 2), followed by functional characterization.
Engineering of lanthipeptides has been carried out in producer strains or via
heterologous expression (6, 7, 28, 32–34). In this study, the nisin biosynthesis system
was used to produce 20 peptides with double lipid II binding motifs. Of the designed
peptides, two showed potent antimicrobial activity against Micrococcus flavus. These
two active peptides have relatively longer backbones than others, allowing the two
different lipid II binding motifs to bind to different lipid II units. The MIC assay showed
that TL19 has potent antibacterial activity against the human pathogen E. faecium,
including the antibiotic-resistant strains. Two-component haloduracin showed better
antimicrobial activity against E. faecium than against E. faecalis and Staphylococcus
aureus (35), indicating that the haloduracin lipid II binding motif and its surrounding
residues in TL19 might be the cause of the relatively higher target specificity to E.
faecium. Moreover, the specificity toward E. faecium strains might also relate to a
possibly altered makeup of the cell wall of E. faecium, but this would require additional
studies, because such biochemical analysis is lacking in the literature. Importantly, the
fact that TL19 has higher activity than nisin against E. faecium strains shows that the
additional lipid II binding site can completely compensate for the loss of pore-forming
activity (a property that nisin, haloduracin, and many other lantibiotics have). The
thioether rings in lantibiotics are essential for their potent antimicrobial activity, and in
general, disruption of a ring results in severe reduction or abolishment of antimicrobial
activity (15, 36–38). TL19 had a 4-fold higher antibacterial activity against E. faecium
than the incompletely modified TL17, which indicates that full ring formation is
essential for the optimal antimicrobial activity of this two lipid II binding motifs-
containing peptide. These results are consistent with previous research which showed
that ring C of HalA1 is essential for the antimicrobial activity of haloduracin (15). TL19
did not show pore formation capability but showed 64-fold higher antimicrobial
activity against E. faecium than nisin(1-22) (Table 2), which has only one lipid II binding
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site. These results highlight the key content of this study, which is the demonstration
that the introduction of two lipid II binding motifs into one molecule is a novel and
viable approach to engineer potent antimicrobial peptides.
Thin-layer chromatography is widely used to analyze the peptide and lipid II binding
stoichiometry (14, 20, 29). Previous studies showed that both nisin and HalA1 bind the
peptidoglycan precursor lipid II with 2:1 stoichiometry (11, 16). In contrast, NAI-107
binds lipid II in a 1:1 ratio (NAI-107/lipid II), which then transiently converts to a 2:1 ratio,
possibly as a result of a second step of NAI-107 dimerization (20). In this study,
thin-layer chromatography was used to analyze the binding stoichiometry of TL19 and
lipid II. The results showed that TL19 completely immobilizes lipid II when present at 1:1
FIG 5 Importance of both lipid II binding motifs for antimicrobial activity against E. faecium LMG16003. MALDI-TOF MS data of TL19 or TL19 mutants before
(blue) and after (red) treated with CDAP. (a) TL19 (2Asp); (b) TL19 (34Ala); (c) TL19 (2Asp, 34Ala). (d) Antimicrobial activity for TL19 mutants against E. faecium
LMG16003: 1, TL19 (1 nmol); 2, TL19 (2Asp) (1 nmol); 3, TL19 (34Ala) (1 nmol); 4, TL19 (2Asp, 34Ala) (1 nmol); 5, TL19 (2Asp) (1 nmol) plus TL19 (34Ala) (1 nmol);
6, negative control (buffer).
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stoichiometry. Furthermore, a spot-on-lawn assay showed that the antimicrobial activ-
ity of nisin was abolished by lipid II at a 1:1 (nisin/lipid II) ratio. In contrast to nisin, to
abolish the antimicrobial activity of TL19, a 1:2 (TL19/lipid II) ratio was required. These
results indicate that both lipid II binding motifs in TL19 bind lipid II, which may
contribute to its potent antimicrobial activity. The combination of two different lipid II
binding sites in one molecule may cause an overall stronger target-binding affinity.
Mutagenesis of lantibiotics has been widely performed to improve the therapeutic
potential of peptides or investigate the structure-activity relationship of new peptides
(15, 32, 34, 37, 39–42). In this study, the novel lantibiotic TL19 was produced by the
nisin biosynthesis system. The introduction of a T2D mutation in TL19 almost abolished
the antimicrobial activity of TL19. This result is consistent with previous studies, which
showed that mutant 2T to D abolished the antimicrobial activity of nisin (see Fig. S4)
and that HalA1 alone did not have antibacterial activity (8). The E34A mutant of TL19
also severely reduced the antimicrobial activity of the peptide. These results are
consistent with previous studies on haloduracin (8), which showed that a highly
conserved glutamate in HalA1 (Glu22) was essential for binding to its target lipid II (12,
15, 16). The T2D and E34A double mutant of TL19 decreased or completely abolished
the antimicrobial activity of the peptide. All of the results from these three mutants
clearly demonstrate that both lipid II binding sites are essential for the potent antimi-
crobial activity of TL19.
In conclusion, our results show that the nisin biosynthetic system can successfully be
used to engineer and produce a lantibiotic (TL19) with seven thioether rings and two
lipid II binding motifs. The engineered two lipid II binding motifs-containing TL19
shows higher antimicrobial activity against specific pathogens than nisin(1-22), which
has only one lipid II binding motif. In particular, TL19 shows 64-fold higher antimicrobial
activity against difficult-to-treat enterococci than nisin(1-22) and 2- to 4-fold higher
activity than nisin itself against E. faecium. This study provides a new approach for the
biosynthesis of potent lantibiotics with two different lipid II binding motifs to treat
antibiotic-resistant pathogens.
MATERIALS AND METHODS
General materials and methods. Reagents used for molecular biology experiments were purchased
from Thermo Fisher Scientific (Waltham, MA). Other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO). L. lactis NZ9000 was used as the host cell for plasmid maintenance and protein expression.
Constructed plasmids were sequenced at Macrogen Inc. (Amsterdam, The Netherlands).
Molecular biology techniques. Oligonucleotide primers used for PCR, cloning, and sequencing in
this study are provided in Table S1 in the supplemental material; all of the oligonucleotide primers were
purchased from Biolegio B.V. (Nijmegen, The Netherlands). Plasmids encoding the peptides were
constructed by amplifying the template plasmid using a phosphorylated downstream sense (or upstream
antisense) primer and an upstream antisense (or downstream sense) primer. Phusion DNA polymerase
(Thermo Fisher Scientific, Waltham, MA) was used to amplify the DNA. Self-ligation of the PCR product
was carried out with T4 DNA ligase (Thermo Fisher Scientific, Waltham, MA). The electrotransformation
of L. lactis was carried out as previously described using a Bio-Rad gene pulser (Bio-Rad, Richmond, CA)
(43). The mutations were verified by sequencing using the PrXZ12 reverse primer.
Expression and trichloroacetic acid precipitation of peptides. L. lactis NZ9000 cells containing the
genes of the nisin synthetic machinery nisBTC were electroporated with His6 peptide plasmids (50 ng),
plated on GM17 agar plates supplemented with chloramphenicol (5 g/ml) and erythromycin (5 g/ml)
(GM17CmEm), and grown at 30°C for 20 to 24 h. A single colony was used to inoculate 5 ml of
GM17CmEm broth. The culture was grown overnight at 30°C and then used to inoculate 45 ml (20-fold
dilution) of minimal medium. Cultures were grown at 30°C to an optical density at 600 nm (OD600) of 0.4.
Peptide expression was induced by the addition of nisin to a final concentration of 5 ng/ml, and cultures
were grown at 30°C for 3 h. Cells were harvested by centrifugation at 15,000  g for 15 min, and
supernatants were collected. Ice-cold 100% trichloroacetic acid (TCA) was added to the ice-cold super-
natants to a final concentration of 10%, and samples were subsequently kept on ice for 1 h to precipitate
peptides. Samples were then centrifuged at 10,000  g at 4°C for 30 min. The precipitate was washed
several times with 20 ml ice-cold acetone to remove any residual TCA. Samples were dried in the fume
hood and resuspended in 0.5 ml phosphate-buffered saline (PBS).
Tricine-SDS protein gel assay. Peptides isolated from the supernatant were separated by Tricine-
SDS gel (16%) electrophoresis and visualized by Coomassie blue staining.
Screening the antibacterial activity of peptides by spot-on-lawn assay. To assess the antibac-
terial activity of TCA-precipitated samples on a agar plate, an overnight culture of Micrococcus flavus was
added to the GM17 containing 0.8% (wt/vol) agar (at 42°C), and then the mixture was poured onto the
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plates, 30 ml per plate. After that, 5 l of the peptides together with 1 l of NisP were added to the
plates, and the plates were transferred to the 30°C incubator for incubation overnight.
Expression and purification of His6-tagged peptides. L. lactis NZ9000, containing the plasmids
with the genes of the nisin synthetic machinery and of the designed peptide, was used to inoculate 50 ml
of GM17CmEm broth. The culture was grown overnight at 30°C and then used to inoculate 1 liter (20-fold
dilution) of GM17CmEm medium. Cultures were grown at 30°C to an OD600 of 0.4. Peptide expression was
induced by the addition of nisin to a final concentration of 5 ng/ml, and cultures were grown at 30°C for
3 h. After centrifugation at 15,000  g for 15 min, supernatants were collected, the pH of the supernatant
was adjusted to 7.4, and the supernatant was filtered through a 0.45-m membrane. Supernatants were
applied to a HisTrap Excel column (GE Healthcare) equilibrated with 50 mM NaH2PO4, 300 mM NaCl, and
10 mM imidazole (pH 8.0). The flowthrough was discarded, and the column was subsequently washed
with 16 column volumes (CV) of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole [pH 8.0]).
The peptide was eluted with 15 CV elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole [pH
8.0]). The eluted peptide was then applied to a Sigma-Aldrich C18 silica gel spherically equilibrated first
with 8 CV of acetonitrile (MeCN) containing 0.1% trifluoroacetic acid followed by 8 CV of 5% aqueous
MeCN containing 0.1% trifluoroacetic acid. The column was washed with 8 CV of 5% aqueous MeCN
containing 0.1% trifluoroacetic acid to remove the salts. Peptide was eluted from the column using up
to 8 CV of 50% aqueous MeCN containing 0.1% trifluoroacetic acid. Fractions containing the eluted
peptide were freeze-dried, and the peptide was subsequently dissolved in PBS containing an appropriate
amount of NisP and incubated at 37°C for 2 h to cleave off the leader peptide. The insoluble material was
removed by filtration through a 0.2-m filter, and the supernatant was purified on an Agilent 1260
Infinity HPLC system with a Phenomenex Aeris C18 column (250 mm by 4.6 mm, 3.6-m particle size,
100-Å pore size). Acetonitrile was used as the mobile phase, and a gradient of 35% to 40% aqueous
MeCN over 18 min at 1 ml/min was used for separation. Peptide was eluted at 37% to 38% MeCN.
Mass spectrometry. Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass
spectrometer analysis was performed using a 4800 Plus MALDI TOF/TOF analyzer (Applied Biosystems)
in the linear-positive mode at University of Groningen. Briefly, a 1-l sample from HPLC or TCA
precipitation was spotted on the target and dried at room temperature. Subsequently, 0.6 l of matrix
solution (5 mg/ml of -cyano-4-hydroxycinnamic acid) was spotted on each sample. After the samples
had dried, MALDI-TOF MS was performed.
Evaluation of (methyl)lanthionine formation. After the freeze-dried samples were dissolved in
18 l of 0.5 M HCl (pH 3), the samples were treated with 2 l of 100-mg/ml tris[2-carboxyethyl]phosphine
in 0.5 M HCl (pH 3) for 30 min at room temperature. Subsequently, the samples were treated with 4 l
of 100-mg/ml 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) in 0.5 M HCl (pH 3). After
incubation at room temperature for 2 h, the samples were desalted by C18 ZipTip (Millipore) and analyzed
by MALDI-TOF MS (42, 44).
MIC. MIC was evaluated by broth microdilution according to the standard guidelines (45). Briefly, the
test medium was cation-adjusted Mueller-Hinton broth (MHB). Cell concentration was adjusted to
approximately 5  105 cells per ml. After 20 h of incubation at 37°C, the MIC was defined as the lowest
concentration of antibiotic with no visible growth. Each experiment was performed in triplicates.
Time-kill assay. This assay was performed according to a previously described procedure (29). An
overnight culture of cells (Enterococcus faecium LMG 16003; vancomycin-resistant strain) was diluted
50-fold in MHB and incubated at 37°C with aeration at 220 rpm. Bacteria were grown to an OD of 0.5,
and then the cell concentration was adjusted to 5  105 cells per ml. Bacteria were then challenged
with nisin (20 M), nisin(1-22) (600 M), or TL19 (10 M) in culture tubes at 37°C and 220 rpm. (peptides
at 10 MIC, a desirable concentration at the site of infection). Bacteria not treated with peptides were
used as a negative control. At desired time points, 100-l aliquots were taken, centrifuged at 8,000  g
for 2 min, and resuspended in 100 l of MHB. Ten-fold serially diluted samples were plated on Mueller-
Hinton agar (MHA) plates. After incubating at 37°C overnight, colonies were counted and CFU per
milliliter was calculated. Each experiment was performed in triplicates.
Propidium iodide assay for membrane pore formation. The excitation and emission wavelengths
on the fluorescence spectrometer were adjusted to 533 nm and 617 nm, respectively. E. faecium
LMG16003 was grown to an OD600 of 0.6. To this cell suspension, propidium iodide (final concentration,
2.5 g per ml) was added and incubated for 5 min. Peptides were added to a final concentration of 3 M.
Fluorescence was monitored for 3 h, with the peptide added after 60 s. Representative examples from
three technical replicates are shown in the figures.
Analysis of complex formation of TL19 with lipid II by thin-layer chromatography. Purified lipid
II-lys or lipid II-dap (4 nmol) was incubated in chloroform-methanol-water (2:3:1), in the presence of
increasing TL19 concentrations (TL19/lipid II molar ratios ranging from 0.3 to 2:1) in a total volume of
30 l. After incubating for 30 min at 25°C, the mixture was analyzed by thin-layer chromatography
using chloroform-methanol-water-ammonia (88:48:10:1), and the spots were visualized by iodine vapor
(20, 26).
Spot-on-lawn assay to measure TL19-lipid II complex formation. An overnight cultured E. faecium
LMG16003 was added to 0.8% MHA (wt/vol; temperature, 42°C) at a final concentration of 0.1% (vol/vol),
and then the mixture was poured onto the plates (30 ml for each). Binding of peptide and lipid II was
further evaluated by incubating purified lipid II with peptide in various molar ratios ranging from 0.5 to
2 with respect to the peptides (1 nmol). Subsequently, a spot-on-lawn assay was used to analyze the
antimicrobial activity. After the lipid II solution drops with peptide had dried, the plates were transferred
to the 37°C incubator for overnight incubation.
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